Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 2/20 | 0.37 |
| ▸ | FFAR2 | O15552 | 3/20 | 0.36 |
| ▸ | CNR1 | P21554 | 5/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | RXRB | P28702 | 1/20 | 0.34 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658750 | 0.93 | KEAP1 (0.37) | FFAR2RXRARXRBRXRGPARP1 | |
| SCHEMBL2656112 | 0.92 | KMT2A (0.41) | ACACBFFAR2CNR1RXRARXRB | |
| SCHEMBL2656898 | 0.88 | ECE1 (0.38) | FFAR2CNR1CNR2LTB4R2PTGER4 | |
| SCHEMBL2643708 | 0.85 | GCGR (0.42) | FFAR2CNR1CNR2LTB4R2PTGER4 | |
| SCHEMBL2643423 | 0.85 | GCGR (0.42) | FFAR2CNR1CNR2LTB4R2PTGER4 | |
| SCHEMBL2643418 | 0.85 | GCGR (0.42) | FFAR2CNR1CNR2LTB4R2PTGER4 | |
| SCHEMBL2643622 | 0.85 | GCGR (0.42) | FFAR2CNR1CNR2LTB4R2PTGER4 | |
| SCHEMBL2644721 | 0.85 | GCGR (0.42) | FFAR2CNR1CNR2LTB4R2PTGER4 | |
| SCHEMBL2655616 | 0.84 | FFAR2 (0.43) | FFAR2CNR1CNR2 | |
| SCHEMBL2643586 | 0.84 | GCGR (0.42) | FFAR2CNR2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203946-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | ACACB 591/4885FFAR2 40/4885CNR1 521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.